Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vascular Endothelial Growth Factor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    102 result(s) found for: Vascular Endothelial Growth Factor. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2014-000103-27 Sponsor Protocol Number: Eylea-2014 Start Date*: 2014-03-12
    Sponsor Name:
    Full Title: Plasma levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept in patients with exudative age-related macular degeneration.
    Medical condition: Exudative age-related macular degeneration (AMD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002826-31 Sponsor Protocol Number: V1 Start Date*: 2007-11-09
    Sponsor Name:Medical University of Vienna
    Full Title: Response of retinal vessels to anti vascular endothelial growth factor (VEGF) treatment in patients with branch retinal vein occlusion (BRVO)
    Medical condition: Cystoid macular oedema due to branch retinal vein occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000973-38 Sponsor Protocol Number: 14-026 Start Date*: 2014-05-14
    Sponsor Name:RWTH Aachen vertreten durch das CTC-A
    Full Title: Xenon-inhalation: elimination of xenon and its effect on erythropoetin-levels in blood of healthy volunteers
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005417-38 Sponsor Protocol Number: CRFB002G2301 Start Date*: 2013-07-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to ...
    Medical condition: Visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10060837 Choroidal neovascularization LLT
    17.0 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) IT (Completed) LV (Completed) PT (Completed) HU (Completed) CZ (Completed) ES (Completed) LT (Completed) BE (Completed) GR (Completed) DK (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-002940-22 Sponsor Protocol Number: STARDUST Start Date*: 2021-01-13
    Sponsor Name:A.O.U. Università degli Studi della Campania "Luigi Vanvitelli"
    Full Title: EFFECTS OF THE GLP-1 RECEPTOR AGONIST LIRAGLUTIDE ON LOWER LIMB PERFUSION IN PEOPLE WITH TYPE 2 DIABETES AND PERIPHERAL ARTERY DISEASE: A RANDOMIZED CONTROLLED TRIAL
    Medical condition: Peripheral Artery Disease and type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10053246 Type II diabetes peripheral angiopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005418-20 Sponsor Protocol Number: CRFB002G2302 Start Date*: 2013-07-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due ...
    Medical condition: Visual impairment due to vascular endothelial growth factor (VEGF) driven macular edema (ME)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10025415 Macular oedema PT
    17.0 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) IT (Completed) GB (Completed) LV (Completed) HU (Completed) CZ (Completed) IE (Completed) ES (Completed) BE (Completed) NL (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-003879-42 Sponsor Protocol Number: 2021/ABM/03/00006 Start Date*: 2023-04-12
    Sponsor Name:Medical Univeristy of Bialystok
    Full Title: A randomized, controlled, double-blind clinical trial evaluating the effect of METformin treatment on endometrial function in women diagnosed with Idiopathic Infertility
    Medical condition: Potential causes of idiopathic infertility include in particular: abnormal function of the endometrium, including implantation disorders and immunological abnormalities, genetic abnormalities and t...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10016471 Fertility and fertilisation interventions female HLT
    20.0 10038604 - Reproductive system and breast disorders 10021928 Infertility female PT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002419-14 Sponsor Protocol Number: IRST189.04 Start Date*: 2015-09-02
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Phase II study of oral PRednisone 5 mg bid plus EVerolimus in patients with metastatic renal cell cancer after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (PRE...
    Medical condition: metastatic renal cell cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-004811-53 Sponsor Protocol Number: PMX GE IT 304 Start Date*: 2005-04-28
    Sponsor Name:PIERRE FABRE PHARMA
    Full Title: Ex-vivo study regarding the effects of Serenoa r. on the expression of VEGF vascular endothelial growth factor and microvessel density in patients with benign prostatic hypertrophy
    Medical condition: benign prostatic hypertrophy
    Disease: Version SOC Term Classification Code Term Level
    6.1 10004446 PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001722-92 Sponsor Protocol Number: 1 Start Date*: 2005-10-12
    Sponsor Name:The Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery
    Full Title: Systemic Bevacizumab (Avastin®) Therapy for Exudative Neovascular Age-Related Macular Degeneration (BEAT-AMD-Study)
    Medical condition: Age related macular degeneration (AMD) patients with fibrovascular pigment epithelium detachment (PED), subfoveal choroidal neovascularisations (CNV) extending under the geometric center of the fov...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020426-18 Sponsor Protocol Number: IMCLCP12-0922 Start Date*: 2010-10-27
    Sponsor Name:ImClone LLC
    Full Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinom...
    Medical condition: Metastatic gastric or gastroesophageal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HU (Completed) RO (Completed) FR (Completed) GB (Completed) AT (Completed) LT (Completed) PT (Completed) EE (Completed) IT (Completed) BE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-005460-28 Sponsor Protocol Number: CRAD001L2401 Start Date*: 2008-07-18
    Sponsor Name:Novartis Farmacéutica, S.A
    Full Title: Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con inhibidor de tirosina quinasas del receptor...
    Medical condition: Pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con inhibidor de tirosina quinasas del receptor del factor de crecimiento endotelial vascular
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) AT (Completed) SK (Completed) CZ (Completed) FI (Completed) SE (Completed) HU (Completed) GB (Completed) BE (Completed) GR (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-000044-71 Sponsor Protocol Number: V3Aug2008 Start Date*: 2006-10-02
    Sponsor Name:University Hospitals of Leicester NHS Trust Research & Development Department
    Full Title: Randomised controlled trial of the effects of fish oil emulsion in total parenteral nutrition upon tumour vascularity in patients with hepatic colorectal metastases
    Medical condition: Potentially resectable hepatic (liver) metastases from colorectal (bowel) cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000294-33 Sponsor Protocol Number: LX201-02 Start Date*: 2007-07-27
    Sponsor Name:Lux Biosciences, Inc.
    Full Title: A MULTI-CENTER, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL-GROUP, DOSE-RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF LX201 IMPLANTATION FOR THE PREVENTION OF CORNEAL ALLOGRAFT REJECTION EPISODES...
    Medical condition: Patient after penetrating keratoplasty who have experienced one or more rejection episodes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011017 Corneal graft rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000295-16 Sponsor Protocol Number: LX201-01 Start Date*: 2007-07-27
    Sponsor Name:Lux Biosciences, Inc.
    Full Title: A MULTI-CENTER, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL-GROUP DOSE-RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF LX201 FOR PREVENTION OF CORNEAL ALLOGRAFT REJECTION EPISODES AND GRAFT FAILURE...
    Medical condition: Patient after penetrating keratoplasty who are at increased immunological risk for corneal allograft rejection episodes and/or graft failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011017 Corneal graft rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006728-73 Sponsor Protocol Number: GENOM-008 Start Date*: 2009-03-09
    Sponsor Name:GRUPO ESPAÑOL DE NEUROONCOLOGIA MEDICA
    Full Title: Ensayo Clínico abierto, fase II, de tratamiento neo-adyuvante de Sunitinib (SU11248) previo al tratamiento con irradiación y concomitante a la misma, en pacientes con Glioblastoma RPA-V-VI y sólo b...
    Medical condition: Glioblastoma clase RPA V-VI, no resecable
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005452-24 Sponsor Protocol Number: KvL Start Date*: 2008-10-30
    Sponsor Name:Fertilitetsklinikken, Afsnit 455, Gynækologisk-Obstetrisk Afdeling, Hvidovre Hospital
    Full Title: Kort versus lang reagensglasbehandling. En prospektiv, konsekutiv og randomiseret sammenlignende undersøgelse.
    Medical condition: Infertility
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038604 - Reproductive system and breast disorders 10021926 Infertility PT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000284-17 Sponsor Protocol Number: VinoMetro2015-007 Start Date*: 2016-11-11
    Sponsor Name:Universitätsmedizin Mainz
    Full Title: Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy (VinoMetro).
    Medical condition: HR+/HER2- advanced/metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004035-38 Sponsor Protocol Number: GIM16-FEVEX Start Date*: 2015-06-17
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: Fulvestrant ed EVerolimus più EXemestane nel carcinoma mammario metastatico” “Fulvestrant followed by everolimus plus exemestane vs examestane and everolimus followed by fulvestrant in postmenopaus...
    Medical condition: Hormone receptor positive (HR+) and human epidermal growth factor receptor type 2 negative (HER2-) locally advanced (LABC) or metastatic breast cancer (MBC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001724-35 Sponsor Protocol Number: AMASCIS-02 Start Date*: 2020-06-16
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario de La Paz (FIBHULP)
    Full Title: AMASCIS-02. ALOGENIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS IN ISCHEMIC STROKE. A PHASE IIB MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED CLINICAL TRIAL.
    Medical condition: Moderate-severe ischemic stroke
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004852 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:26:29 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA